Anavex Life Sciences Corp.

ANAVEX LIFE SCIENCES CORP. is a clinical stage biopharmaceutical company focused on developing distinct treatments using precision medicine for central nervous system (CNS) diseases with significant unmet medical needs. The company examines genomic data from clinical trials to pinpoint biomarkers, which are then utilized in the analysis of its clinical trials for neurodegenerative and neurodevelopmental diseases. ANAVEX LIFE SCIENCES CORP. concentrates on creating new treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. To date, the company has not generated any revenue from its operations. All of the company's potential drug compounds are in the clinical development stage. Management believes that the current working capital position will be sufficient to meet the company's working capital requirements beyond the next 12 months after the date that these consolidated financial statements are issued.